Fenwick Represents Contraline in $92.5M Series B Funding

Fenwick represented Contraline, a clinical-stage biopharmaceutical company developing novel male contraceptives, in its $92.5 million Series B funding. The round was co-led by BVF Partners L.P. and RA Capital Management, with participation from GV (Google Ventures), Lumira Ventures, Invus, and other new and existing investors.

Contraline will use the funds to support the late-stage development of NES/T Gel, an investigational, daily, hormonal, reversible male contraceptive with first-in-class potential, as well as other pipeline assets. More information can be obtained from the company’s website.

The Fenwick transaction team was led by corporate partners Michael Esquivel and Taimur Case and included associates Lindsey Macalalad and Tiana Wang.